Combination of Volasertib and Rapamycin Inhibits the Regrowth of TSC2-Deficient Tumors
M. Valianou, E. Y. Zhang, D. L. Johnson, R. Meyers, M. M. Markiewski, M. Karbowniczek, L. M. Pfeffer, J. J. Yu, J. J. Bissler, A. Astrinidis
This study shows that combining volasertib and rapamycin inhibits tumor regrowth in TSC2-deficient models more effectively than rapamycin alone.
bioRxiv · Nov 2, 2022 · PreprintCancer Biology